Pharmaceutical

Veraxa to go public in $1.6bn SPAC deal with Voyager

Veraxa Biotech will gain access to $253m in cash from Voyager to advance its can...

Synthetic hormones and the future of contraception

Contraception for women has seen little change over the past 50 years, with the ...

EditCo Bio secures access to Promega’s technologies in ...

EditCo Bio has entered a licensing agreement to secure access to Promega’s prote...

FDA layoffs and priority review programme’s lapse disru...

The expiration of the FDA’s paediatric priority review voucher programme is crea...

Boehringer to expand oncology presence with $572m Tesse...

The agreement gives Boehringer access to Tessellate’s novel approach targeting A...

ConcertAI and Bayer to boost precision oncology with AI...

ConcertAI has announced an agreement with Bayer that allows the latter to utilis...

TNF and Renova Health use AI to identify patients for G...

TNF and Renova Health are set to use AI and ML for the identification of high-ri...

First two medicinal products to undergo EU joint clinic...

In April 2025, the EU announced details about the first two medicinal products t...

Biogen’s Friedreich’s ataxia treatment authorised in UK

Biogen Netherlands has received marketing authorisation from the UK MHRA for its...

Eli Lilly sues Mochi Health and others for ‘deceptive’ ...

The lawsuit filings are the latest turn in a long-running legal saga between GLP...

Roche announces $50bn US investment in pharma and diagn...

Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over t...

FDA grants breakthrough status to uniQure’s Huntington’...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy desig...

UK’s MHRA authorises GSK’s Blenrep for multiple myeloma...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authoris...

Sanofi and Regeneron’s dupilumab approved by FDA for ur...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for...

ACIP recommends GSK’s RSV vaccine for at-risk adults 50...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vac...